Correction to: Association of the Pro12Ala gene polymorphism with treatment response to thiazolidinediones in patients with type 2 diabetes: a meta-analysis (International Journal of Diabetes in Developing Countries, (2022), 10.1007/s13410-022-01086-z)

Johana Vallo, Angeles University Foundation
Roselle Arbas, Angeles University Foundation
Jan Erika Basilio, Angeles University Foundation
Ivy Cayabyab, Angeles University Foundation
Christian Noel Miranda, Angeles University Foundation
Ma Paulina Isabel Santos, Angeles University Foundation
Louie Fernand Legaspi, De La Salle Medical and Health Sciences Institute
Raphael Enrique Tiongco, Angeles University Foundation


Background/purpose of the study: With the conflicting results on available studies regarding the association of the Pro12Ala polymorphism with the response of patients with type 2 diabetes mellitus (T2DM) to thiazolidinediones (TZDs), this meta-analysis was conducted to obtain more precise estimates. Methods: Relevant studies were searched in PubMed and Google Scholar and were selected according to the set inclusion criteria. Data were extracted and analyzed using both Review Manager 5.4.1 and Meta-Essentials. Pooled mean difference (MD), standardized mean difference (SMD), and odds ratios (ORs) and their 95% confidence intervals were computed to measure the association of the polymorphism with TZD treatment response. Results: Only four studies were included in this meta-analysis, with a sample size of 680. The pooled MD analysis results showed that FBG and HbA1c are significantly higher in the post-intervention group than in the pre-intervention group. No significant differences were noted between the genotypic groups (Pro12Pro vs. Pro12Ala and/or Ala12Ala). On the other hand, pooled OR analysis showed that T2DM that carry the PPARG gene variant are more likely to respond to TZD therapy. Conclusion: Based on the results of this meta-analysis, our findings suggest that the presence of the PPARG gene variant is associated with the response of patients with T2DM to TZD therapy. However, further studies are still needed to verify our claims.


In Table 3, last column 4th row under PA, it should be 0.0003**. 18 19 The Original article has been corrected.